IP Verse

Sglt-2 Inhibitor For Use In The Treatment Of A Metabolic Myopathy - EP3362055B1

PatentPatent Analysis

EP3362055

BOEHRINGER INGELHEIM
Application Number
EP16781135A
Filing Date
Oct 13, 2016
Status
Revoked
May 17, 2024
Grant Date
Jan 18, 2023
External Links
Slate, Register, Google Patents
Similar Patents facing opposition
EP2488145B1
EP3150200B1
EP2395968B1

Bibliography

The patent EP3362055B1 was granted to Boehringer Ingelheim on Jan 18, 2023 following the initial filing on Oct 13, 2016 under the application number EP16781135A . The current legal status of the patent is Revoked.

AI Generated Summary New

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

GENERICS UKOct 17, 2023ADMISSIBLE
SANDOZOct 6, 2023ADMISSIBLE

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents